Influenza B is an acute respiratory infection caused by Influenza B viruses, typically presenting with sudden high fever, chills, body aches, and dry cough. The core difference lies in their biology: Influenza A mutates rapidly across animal and human reservoirs to cause global pandemics, whereas Influenza B circulates almost exclusively among humans. However, Influenza B tends to trigger gastrointestinal symptoms and calf muscle pain more frequently in children and adolescents. Because their initial symptoms overlap significantly, clinical swab testing is required for definitive differentiation.
After contracting Influenza B, symptoms typically develop abruptly within a matter of hours:
Clinical observations show that children and adolescents with Influenza B are significantly more prone to digestive tract involvement than adults or Influenza A patients. Along with fever, paediatric patients frequently suffer from sudden loss of appetite, nausea, frequent vomiting, periumbilical abdominal pain, and watery diarrhoea. These gastrointestinal complaints often lead parents to suspect acute gastroenteritis or food poisoning, potentially delaying timely respiratory diagnosis and antiviral treatment.
Although both Influenza A and Influenza B belong to the Orthomyxoviridae family, they exhibit distinct biological and epidemiological differences:
| Comparison Parameter | Influenza A | Influenza B |
|---|---|---|
| Primary Natural Hosts | Humans, birds, pigs, horses, and various mammals | Almost exclusively humans and select marine mammals |
| Mutation Capability | Extremely high; undergoes antigenic shift and drift | Moderate; undergoes antigenic drift only |
| Epidemic Scale | High pandemic potential across global populations | Regional seasonal epidemics or local school clusters |
| Main Strain Classifications | Subtypes such as H1N1 and H3N2 | Lineages: Victoria and Yamagata |
| Gastrointestinal Prevalence | Relatively lower; primarily severe respiratory symptoms | Significantly higher, particularly vomiting and diarrhoea in children |
| Muscular Involvement | Diffuse general myalgia | Diffuse myalgia, plus higher risk of benign acute childhood myositis (calf pain) |
Doctors cannot reliably distinguish Influenza A from Influenza B based purely on fever severity or cough. In Malaysia, anyone experiencing suspected flu symptoms should visit a nearby private general practitioner clinic (Klinik GP) or medical centre. Doctors typically collect a nasal or nasopharyngeal swab sample to perform a rapid influenza antigen test (RTK).
This test delivers results within 15 to 20 minutes, indicating whether a patient is positive for Influenza A, Influenza B, or negative. This provides the essential diagnostic confirmation required before initiating targeted antiviral therapies.
Influenza B is highly contagious, spreading through airborne respiratory droplets expelled when an infected person coughs, sneezes, or talks, as well as indirect contact with contaminated surfaces followed by touching the eyes, nose, or mouth. The incubation period typically ranges from 1 to 4 days (averaging around 2 days), with viral shedding beginning approximately 24 hours before symptoms appear. Peak viral shedding occurs during the first 5 to 7 days of illness. The Ministry of Health Malaysia (KKM) and infectious disease experts advise confirmed patients to self-isolate at home for at least 5 to 7 days to curb transmission in workplaces and schools.
Tamiflu (generic name: Oseltamivir) is a first-line oral antiviral medication used to treat Influenza B. As a neuraminidase inhibitor, it blocks mature viruses from detaching from host cells and spreading to adjacent tissues. Efficacy depends heavily on initiating treatment within the ‘golden 48 hours’ of symptom onset, which can shorten illness duration by 1 to 2 days and lower the risk of complications such as pneumonia. In Malaysia, Tamiflu is a strictly regulated prescription medication that requires an evaluation and prescription from a registered medical practitioner.
Once Influenza B viruses infect respiratory epithelial cells and replicate, they rely on the surface enzyme neuraminidase to sever connections with host cells and infect neighbouring tissues. Tamiflu specifically inhibits this enzyme, trapping newly formed virions inside host cells and halting unchecked viral replication.
Clinical trials demonstrate that starting treatment within the first 48 hours of symptom onset yields optimal outcomes. Early administration curbs viral load, mitigates fever intensity and systemic toxicity, and reduces the likelihood of severe secondary pneumonia, acute otitis media, and hospitalisation. If more than 48 hours have elapsed, antiviral therapy may still be clinically indicated for high-risk patients—such as children under 5, adults aged 65 and above, pregnant women, and individuals with underlying chronic cardiopulmonary conditions.
Tamiflu is available in oral capsules and oral suspension formulations. The standard adult therapeutic dosage is 75 mg taken orally twice daily, while paediatric dosages are calculated based on body weight. A standard treatment course requires continuous administration for 5 full days.
Patients must not discontinue the medication early simply because their fever subsides or physical strength improves. Stopping prematurely allows residual viruses to rebound and increases the risk of antiviral drug resistance. Common side effects include mild nausea, vomiting, and abdominal discomfort, which can often be minimised by taking the medication with meals or a light snack.
In Malaysia, Tamiflu is classified as a Group B Poison under the Poisons Act 1952. Under this regulation, retail community pharmacies are prohibited from dispensing the medication over the counter without a valid prescription from a registered medical practitioner.
Patients presenting with fever and flu symptoms should consult a doctor at a private GP clinic (Klinik GP), a public health clinic (Klinik Kesihatan), or a private hospital. Following physical examination and an RTK antigen swab test, the attending doctor can prescribe and dispense the medication directly through the in-house clinic pharmacy or hospital dispensary with clear dosing instructions.
Influenza B often causes more pronounced illness in children than in adults. High fevers recurring over 3 to 5 days are common, and parents need not panic if the child remains alert between fever spikes. Essential home care centres on proper fever management, adequate hydration, airway maintenance, and the strict avoidance of aspirin. Caregivers must also monitor breathing patterns and alertness, seeking emergency medical care if warning signs appear.
In healthy individuals, acute systemic symptoms of Influenza B typically subside within about one week, although damaged respiratory epithelial cells may require 2 to 3 weeks to repair completely. Some individuals may develop secondary bacterial infections or myocarditis, and a subset of children may experience sudden calf pain. Adequate convalescent rest and annual influenza vaccination remain the most reliable strategies to avoid complications and reinfection.
Influenza B is generally a self-limiting viral illness. In healthy adults with mild illness, the immune system typically clears the virus within 7 to 10 days with adequate bed rest, oral hydration, and over-the-counter symptom relief. However, antiviral medication like Tamiflu is strongly recommended within 48 hours for vulnerable groups—including children under 5, adults over 65, pregnant women, and individuals with chronic health conditions—to reduce the risk of severe complications and hospitalisation.
This is usually Benign Acute Childhood Myositis (BACM), a temporary inflammatory condition that typically occurs 24 to 72 hours after flu fever resolves, most commonly in school-aged children. Children develop acute bilateral calf muscle tenderness and may refuse to walk or walk on their tiptoes. It is benign and self-limiting, usually resolving within 3 to 7 days with rest and fluids. Caregivers should monitor urine colour; if it becomes dark or tea-coloured, seek urgent medical care to rule out rhabdomyolysis.
Unlike temperate regions where influenza peaks exclusively in winter, Malaysia experiences year-round influenza transmission due to its tropical climate. However, surveillance data indicates increased flu activity during monsoon transitions—typically between May and July, and between November and January. Flu clusters also occur frequently around school term reopenings and holiday periods when people gather in enclosed air-conditioned spaces.
Antibiotics target bacterial infections and are completely ineffective against influenza viruses. Taking antibiotics unnecessarily will not treat Influenza B and can cause drug resistance or disrupt gut flora. Standard over-the-counter cold remedies only alleviate superficial symptoms such as runny nose or headache; they do not halt viral replication. Effective medical management involves prescription antivirals (when clinically indicated) and supportive care.
This article is for reference only; the actual coverage terms are subject to the policy.
This article is for reference only and is not medical advice. Please consult a registered doctor if you have any concerns.
© 2026 Bowtie Life Insurance Company Limited. All rights reserved.
